Drug Profile
Research programme: antibacterials - Protez Pharmaceuticals
Alternative Names: Antibacterials for slow-growing and biofilm bacteria - Protez Pharmaceuticals; Bacteriocidal potentiators research programme - Protez Pharmaceuticals; Efflux pump inhibitors research programme - Protez Pharmaceuticals; INF 401; INF-271,468; Research programme: bacteriocidal potentiators - Protez Pharmaceuticals; Research programme: efflux pump inhibitors - Protez PharmaceuticalsLatest Information Update: 06 Jun 2008
Price :
$50
*
At a glance
- Originator Protez Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 06 Jun 2008 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
- 23 Sep 2005 This programme is still in active development - BIO-2005 Annual International Convention (BIO-2005)
- 02 Mar 2004 Influx has been acquired by, and merged into, Protez Pharmaceuticals